NASDAQ:SPTX Seaport Therapeutics Q1 2026 Earnings Report $21.77 +0.65 (+3.08%) As of 10:21 AM Eastern ProfileEarnings HistoryForecast Seaport Therapeutics EPS ResultsActual EPS-$10.34Consensus EPS -$10.64Beat/MissBeat by +$0.30One Year Ago EPSN/ASeaport Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ASeaport Therapeutics Announcement DetailsQuarterQ1 2026Date6/8/2026TimeBefore Market OpensConference Call DateMonday, June 8, 2026Conference Call Time7:00AM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Seaport Therapeutics Earnings HeadlinesSeaport Therapeutics to Participate in September Investor ConferencesSeptember 14, 2026 | finance.yahoo.comSeaport Therapeutics to Participate in September Investor ConferencesSeptember 14, 2026 | businesswire.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.September 25 at 1:00 AM | InvestorPlace (Ad)Seaport Therapeutics Says GlyphAllo Shows no Next-Morning Driving Impairment in Phase 1 TrialSeptember 9, 2026 | finance.yahoo.comSeaport Therapeutics Reports Positive Topline Results From Phase 1 Driving Simulation Trial Of GlyphAllo In Healthy VolunteersSeptember 9, 2026 | marketscreener.comMSeaport Reports Positive GlyphAllo Driving Trial Results In Healthy VolunteersSeptember 9, 2026 | rttnews.comSee More Seaport Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Seaport Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Seaport Therapeutics and other key companies, straight to your email. Email Address About Seaport TherapeuticsSeaport Therapeutics (NASDAQ:SPTX) is a clinical-stage biopharmaceutical company focused on developing medicines for central nervous system (CNS) disorders. The company is working to advance treatments for conditions in areas such as psychiatry and neurology, with the goal of addressing significant limitations associated with existing therapies. Seaport’s drug-development efforts are supported by its proprietary Glyph platform, which is designed to enable oral delivery of therapeutics that have historically required injection or infusion. The platform is intended to improve the convenience and potential clinical utility of certain medicines, while supporting the development of a pipeline of novel CNS treatments. Seaport Therapeutics was established with backing from PureTech Health and is led by Chief Executive Officer Daphne Zohar. The company is headquartered in the United States and is conducting research and clinical development aimed at serving patients with CNS disorders in the U.S. and other global markets.View Seaport Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Super Micro’s Vera Rubin Shipments Put Its AI Infrastructure Advantage to the TestHims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks3 Space Stocks to Watch as SpaceX Reshapes the Launch MarketCintas Raises Guidance as a Major Catalyst Moves Closer3 Restaurant Stocks Near 52-Week Lows as Consumer Pressure BuildsPaychex Plunges, Providing the Entry Investors Have Been Waiting ForThe Case for Buying High-Yield General Mills Just Strengthened Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
